MetLife Investment Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

MetLife Investment Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-26,102	Closed	-$135K	–	2467
2019 Q2	$135K	Buy	+26,102	New	+$117K	﹤0.01%	2241
2019 Q1	–	Sell	-23,524	Closed	-$144K	–	2609
2018 Q4	$144K	Hold	23,524	–	–	﹤0.01%	2100
2018 Q3	$137K	Buy	+23,524	New	+$118K	﹤0.01%	2291
2018 Q1	–	Sell	-20,999	Closed	-$110K	–	2237
2017 Q4	$110K	Buy	+20,999	New	+$128K	﹤0.01%	2189

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

MetLife Investment Management's PETX Position: Q3 2019 in Review

MetLife Investment Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 26,102 shares — an estimated $135K sold.

MetLife Investment Management first reported a position in PETX in Q4 2017 and held it in 4 quarters. The position peaked at $144K in Q4 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

MetLife Investment Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
MetLife Investment Management sold 26,102 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $135K.
MetLife Investment Management first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
MetLife Investment Management's Aratana Therapeutics, Inc. position peaked at $144K in Q4 2018.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on MetLife Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.